Compare Crispr Therapeutics AG (CRSP) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs NextEra Energy, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.95 (market cap $4.88B), while NextEra Energy, Inc. trades at $77.39 (market cap $161.39B). The key difference: NextEra Energy, Inc. is far larger — about 33.1× Crispr Therapeutics AG's market cap, and NextEra Energy, Inc. pays a 3.22% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and NextEra Energy, Inc. for 83 Days on average.
| CRSP | NEE | |
|---|---|---|
Market Cap | $4.88B | $161.39B |
Volume | 2,861,747 | 11,780,955 |
Sector | Health | Utilities |
52-Week High | $74.92 | $97.88 |
52-Week Low | $44.34 | $75.49 |
Typical Hold Time | 77 Days | 83 Days |
Enterprise Value | $3.30B | $268.72B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
NextEra Energy (NEE) trades at $77.06, down 1.05% today, near its 52-week low of $74.78. The stock shows mixed signals with a bearish technical outlook but strong fundamentals, including a 32.4% net income margin and recent earnings beats. Recent news highlights growth initiatives like the Project Star energy infrastructure partnership and a dividend of $0.62 payable in September 2026.
NEE offers a compelling valuation with a P/E of 17.39 and a consensus price target of $96, implying 25% upside. Risks include high debt levels and interest rate sensitivity, but analyst sentiment remains bullish with 66.7% buy ratings. The stock is positioned for long-term growth in clean energy, though near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
